Some
anticancer agents induce immunogenic cell death that is accompanied by the emission of danger signals into the tumor microenvironment, thus attracting and activating innate immune effectors and finally inducing anticancer immunity. The release of extracellular
nucleosides such as
adenosine triphosphate (
ATP) from the
tumor in response to anticancer
therapy plays a pivotal role in the attraction of antigen presenting cells and the activation of
inflammasome-mediated proinflammatory cascades. In contrast, the ectonucleotidase-catalyzed phosphohydrolysis of
nucleotides to
nucleosides reduces the extracellular availability of
nucleotides, hence limiting the recruitment and activation of antigen-presenting cells. In addition, the (over-)production of
nucleosides including
adenosine by ectonucleotidases located on
cancer cells and regulatory T cells can induce immunosuppression, as
adenosine directly inhibits the proliferation and activation of effector T cells. Here, we discuss the importance of death metabolites for
immunomodulation in general, and the role of the
purine nucleotide ATP and its derivative
adenosine in particular. In addition, we provide an overview on therapeutic interventions that reinstate
tumor immunogenicity in conditions where
nucleotide-dependent immunostimulation is obstructed.